Sino Biopharmaceutical Limited (HKG:1177)
Hong Kong
· Delayed Price · Currency is HKD 5.46
-0.02 (-0.36%)
Apr 29, 2026, 4:08 PM HKT
Sino Biopharmaceutical Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 97,510 | 110,478 | 58,258 | 63,845 | 84,459 | 102,408 | Upgrade
|
| Market Cap Growth | 35.76% | 89.64% | -8.75% | -24.41% | -17.53% | -27.33% | Upgrade
|
| Enterprise Value | 103,005 | 115,449 | 64,462 | 66,382 | 90,167 | 114,126 | Upgrade
|
| Last Close Price | 5.46 | 6.18 | 3.16 | 3.35 | 4.32 | 5.03 | Upgrade
|
| PE Ratio | 37.80 | 42.37 | 15.64 | 24.85 | 29.37 | 5.71 | Upgrade
|
| Forward PE | 19.00 | 21.62 | 17.48 | 17.77 | 20.63 | 12.33 | Upgrade
|
| PS Ratio | 2.75 | 3.12 | 1.90 | 2.21 | 2.87 | 3.11 | Upgrade
|
| PB Ratio | 2.08 | 2.36 | 1.28 | 1.52 | 1.97 | 2.21 | Upgrade
|
| P/TBV Ratio | 3.71 | 4.20 | 1.78 | 1.96 | 2.59 | 2.84 | Upgrade
|
| P/FCF Ratio | - | - | 9.68 | 11.60 | 14.88 | 22.84 | Upgrade
|
| P/OCF Ratio | - | - | 8.28 | 9.55 | 11.93 | 15.55 | Upgrade
|
| PEG Ratio | 0.95 | 0.84 | 1.24 | 1.34 | - | 0.62 | Upgrade
|
| EV/Sales Ratio | 2.91 | 3.26 | 2.10 | 2.30 | 3.07 | 3.46 | Upgrade
|
| EV/EBITDA Ratio | 12.80 | 14.05 | 8.79 | 9.45 | 12.75 | 17.05 | Upgrade
|
| EV/EBIT Ratio | 15.08 | 16.49 | 10.44 | 11.08 | 14.81 | 20.07 | Upgrade
|
| EV/FCF Ratio | - | - | 10.71 | 12.06 | 15.88 | 25.46 | Upgrade
|
| Debt / Equity Ratio | 0.38 | 0.38 | 0.23 | 0.33 | 0.37 | 0.33 | Upgrade
|
| Debt / EBITDA Ratio | 2.18 | 2.18 | 1.39 | 1.97 | 2.22 | 2.21 | Upgrade
|
| Debt / FCF Ratio | - | - | 1.72 | 2.54 | 2.81 | 3.36 | Upgrade
|
| Net Debt / Equity Ratio | -0.15 | -0.15 | -0.12 | -0.04 | -0.07 | -0.09 | Upgrade
|
| Net Debt / EBITDA Ratio | -0.88 | -0.88 | -0.74 | -0.22 | -0.45 | -0.65 | Upgrade
|
| Net Debt / FCF Ratio | - | - | -0.90 | -0.28 | -0.56 | -0.97 | Upgrade
|
| Asset Turnover | 0.45 | 0.45 | 0.45 | 0.41 | 0.42 | 0.50 | Upgrade
|
| Inventory Turnover | 2.47 | 2.47 | 2.44 | 2.31 | 2.10 | 2.79 | Upgrade
|
| Quick Ratio | 1.16 | 1.16 | 1.11 | 0.90 | 1.15 | 1.38 | Upgrade
|
| Current Ratio | 1.37 | 1.37 | 1.26 | 1.05 | 1.29 | 1.53 | Upgrade
|
| Return on Equity (ROE) | 12.53% | 12.53% | 11.82% | 12.12% | 11.94% | 55.25% | Upgrade
|
| Return on Assets (ROA) | 5.56% | 5.56% | 5.62% | 5.33% | 5.40% | 5.37% | Upgrade
|
| Return on Invested Capital (ROIC) | 13.52% | 13.14% | 14.13% | 12.90% | 13.46% | 15.24% | Upgrade
|
| Return on Capital Employed (ROCE) | 12.40% | 12.40% | 12.70% | 13.30% | 12.30% | 10.30% | Upgrade
|
| Earnings Yield | 2.67% | 2.36% | 6.39% | 4.02% | 3.40% | 17.51% | Upgrade
|
| FCF Yield | - | - | 10.33% | 8.62% | 6.72% | 4.38% | Upgrade
|
| Dividend Yield | 1.82% | 1.62% | 2.20% | 1.46% | 2.78% | 1.59% | Upgrade
|
| Payout Ratio | - | - | 52.76% | 27.13% | 49.84% | 6.42% | Upgrade
|
| Buyback Yield / Dilution | 1.30% | 1.30% | 1.26% | 2.57% | 1.38% | -2.57% | Upgrade
|
| Total Shareholder Return | 3.11% | 2.92% | 3.46% | 4.03% | 4.16% | -0.98% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.